AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

FDA Places Partial Clinical Hold on AbbVie’s Venclexta-Based Multiple Myeloma Trial

In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.

March 19, 2019

2 min read

Alex Keown

BioMidwest

AbbVie’s Humira Remains the Top-Selling Prescription for 2018

Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene’s Revlimid earned about half-as-much in 2018.

March 13, 2019

3 min read

Alex Keown

Drug Development

Takeda’s Entyvio Bests Humira in Head-to-Head UC Study

Takeda Pharmaceutical’s Entyvio outperformed AbbVie’s Humira in a head-to-head comparison in treating ulcerative colitis during a late-stage study, the company said.

March 11, 2019

2 min read

Alex Keown

Job Trends

Top Life Science Companies Hiring Now in March

According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!

February 28, 2019

1 min read

Editorial Staff

BioCapital

Vantage Report 2018: Research Dragged, but Biotech IPOs and Startups Soared

Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.

February 28, 2019

5 min read

Mark Terry

Policy

Gang of 7 Pharma Execs Grilled by Congress

U.S. Senator Chuck Grassley (R-Iowa) set the tone early, mentioning his constituents rationing drugs because of high prices or “leaving their prescription on the pharmacy counter because it costs too much,” but acknowledging that innovations “take time and money.”

February 26, 2019

4 min read

Mark Terry

Business

Voyager and AbbVie Forge Another Neurodegenerative Therapy Collaboration Worth More Than $1 Billion

Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease.

February 22, 2019

2 min read

Alex Keown

Deals

Firmly on our way to becoming a fully integrated biopharma company

FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability

February 21, 2019

12 min read

Policy

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.

February 21, 2019

5 min read

JOBS